Bristol-Myers Squibb Co. said Friday it has halted a late-stage trial of a lung cancer treatment after it met its primary goal, or endpoint. The news sent its shares up almost 3% in early trade. Bristol-Myers said the Phase III trial of Opdivo versus docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) was stopped early after an independent committee found it had demonstrated superior survival rates. The company said it is looking forward to sharing data with the health authorities. Bristol-Myers stock has gained 10.4% in the year so far, while the S&P 500 has gained about 2%.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below